1,2,3,4-tetrahydro-naphthalene-2,3-diamine | 54877-04-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 1,2,3,4-tetrahydro-naphthalene-2,3-diamine
• 英文别名: 1,2,3,4-Tetrahydronaphthalene-2,3-diamine
• CAS: 54877-04-2；54877-05-3
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: QFUDBEIUVLAUMN-UHFFFAOYSA-N

物化性质

• 沸点：
  289.4±40.0 °C(Predicted)
• 密度：
  1.071±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  利福霉素 、 1,2,3,4-tetrahydro-naphthalene-2,3-diamine 生成 (1²S,1^8aΞ,1^14aΞ,3E,5S,13E,15Z)-7t-acetoxy-1^5,6,9c,11t-tetrahydroxy-5r-methoxy-1^2,4,6t,8c,10c,12t,16-heptamethyl-1^8a,9,14,14a-tetrahydro-2-oxa-18-aza-1(2,7)-benzo[i]furo[2',3':5,6]benzo[1,2-a]phenazina-cyclooctadecaphane-3,13,15-triene-1¹,17-dione
  参考文献：
  名称：

  Zur Kenntnis von Rifamycin-S. Reaktionen des chinoiden Nucleus. Modifikationen von Antibiotica, 9. Mitteilung [1]

  摘要：

  AbstractThe reactivity of rifamycin‐S (1) with respect to nucleophilic reagents has been studied. Several new classes of derivatives, some of which show interesting biological activities, are described.

  DOI：

  10.1002/hlca.19730560720

文献信息

• Hepatobiliary magnetic resonance contrast agents
  申请人：Bracco International B.V.

  公开号：EP1184377B1

  公开（公告）日：2005-02-02
• HEPATOBILIARY MAGNETIC RESONANCE CONTRAST AGENTS
  申请人：BRACCO International B.V.

  公开号：EP0670832A1

  公开（公告）日：1995-09-13
• EP3752491A1
  申请人：——

  公开号：EP3752491A1

  公开（公告）日：2020-12-23
• TARGETED NANOVECTORS AND THEIR USE FOR TREATMENT OF BRAIN TUMORS
  申请人：Tour James M.

  公开号：US20140154269A1

  公开（公告）日：2014-06-05

  In some embodiments, the invention pertains to therapeutic compositions for treating a brain tumor. Such therapeutic compositions generally comprise: (1) a nanovector; (2) an active agent associated with the nanovector with activity against brain tumor cells; and (3) a targeting agent associated with the nanovector with recognition activity for a marker of the brain tumor cells. In some embodiments, the active agent and the targeting agent are non-covalently associated with the nanovector. Additional embodiments of the present invention pertain to methods of treating a brain tumor in a subject (e.g., a human being) by administering the aforementioned therapeutic compositions to the subject. Further embodiments of the present disclosure pertain to methods of formulating therapeutic compositions for treating a brain tumor in a subject in a personalized manner.
• METHODS AND COMPOSITIONS FOR TYPING MOLECULAR SUBGROUPS OF MEDULLOBLASTOMA
  申请人：Ellison David

  公开号：US20140155400A1

  公开（公告）日：2014-06-05

  Immunohistochemical methods and compositions for the typing of molecular subgroups of medulloblastomas are provided. The methods comprise determining a protein expression profile for a sample obtained from a medulloblastoma by detecting expression of GAB 1, filamin A, or at least two biomarker proteins selected from the group consisting of β-catenin, YAP1, GAB1, and filamin A, and typing the medulloblastoma as a WNT pathway tumor, a SHH pathway tumor, or a non-WNT/non-SHH tumor based on this protein expression profile. Kits for typing a medulloblastoma according to these three molecular subgroups are provided. The kits comprise at least two antibodies, wherein each of said antibodies specifically binds to a distinct biomarker protein selected from the group consisting of β-catenin, YAP1, GAB1, and filamin A, and can optionally comprise one or more of instructions for use, reagents for detecting antibody binding to one or more of said biomarker proteins, and one or more positive control samples.